Can GSK survive the economic uncertainty?


GlaxoSmithKline plc (GSK) is a UK multinational pharmaceutical company based in London, UK. GSK is the sixth-largest pharmaceutical company in the world, according to Forbes, founded in 2000 after Pfizer, Novartis, Roche, Sanofi, and Merck & Co, with the merger of Glaxo Welcome and SmithKline Beecham. GSK is the 10th largest pharmaceutical company in the 19 Fortune 500 list, after other pharmaceutical companies such as China Resources, Johnson & Johnson, Roche, China National Pharmaceutical, Pfizer, Novartis, Bayer, Merck, and Sanofi. The number is 296.


The company listed on the London Stock Exchange and is a component of the FTSE 100 index, and as of August 2016, with a market capitalization of 81 billion, is the fourth largest London Stock Exchange. This secondary exchange listed on the New York Stock Exchange.

The company developed first malaria, RTS, and S vaccines and announced in 2014 that they would be available at a 5% cost. Heritage products produced at GSK include several products on the World Health Organization’s list of essential drugs, including amoxicillin, mercaptopurine, pyrimethamine, and zidovudine.


In 2012, GSK pleaded guilty to $ 3 billion (1. 1.9 billion) for upgrading drugs for illicit use, failing to report safety data, and returning it to US doctors. This is the largest case of medical fraud in the country to date and the largest case by a pharmaceutical company.


Can GSK survive the economic uncertainty?

Studies show that quality and value are two powerful factors on stock market dividends. Following the economic turmoil of the past year, these two factors may affect the stock price of GlaxoSmithKline (LON: GSK).


Quality and value are important clues for opposing investors looking for stocks that the market is unaware of. Academic research shows that cheap, high-quality strains can perform better over time. Therefore, it is no surprise that these rules used by some of the world’s most respected investors, from Joel Greenblatt to Warren Buffett.

GlaxoSmithKline’s stock price has risen -12.7% in the last three months and is currently trading at 1205.4. However, what is interesting about these stocks is the potential exposure to effective returns from high-quality, relatively inexpensive valuations.



Here is an idea of ​​where to view it:

  • Good Quality

The stock market likes good quality because it is probably a strong and reliable business. Profitability is important, but so is the financial strength of the company. It is essential to record financial progress.

One of the quality indicators of GlaxoSmithKline is passing 7 out of 9 financial tests for F Piotroski score. F-Score is an excellent accounting-based checklist for finding stocks with improved financial trends. A good score of F indicates that the company has strong signs of quality.


  • Fair Price

Quality is important, but attractive evaluations are also necessary because no one wants to pay too much for stocks. Due to the recession, the profit forecast for the whole market is not clear. However, there several criteria that can be useful, one of which is revenue performance.

The performance obtained compares the firm’s revenue with the market valuation (calculated by dividing operating profit by the firm’s value). The total value of the stock (including cash and debt) displayed, so you can easily compare different stocks. As a percentage, the higher the profitability, the higher the value of the share.

A reasonable normal rate of return maybe 5% and the current GlaxoSmithKline rate of return is 8.88%.

In short, relatively cheap and high-quality valuations show some of the most attractive stocks for value-added investors. Some of these stocks may have real fake prices. When the market recognizes that these high-quality companies for sale, their prices often go up.


What does this mean for potential investors?


Finding good stock with cheap prices is a strategy used by some of the most successful investors in the world. Be careful though. These factors do not guarantee future income and have identified some concerns about GlaxoSmithKline that can be identified here.

Alternatively, if you want to find more stocks that show signs of high quality and value, look at this quality and value display.


Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button